---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-056852"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2024-03-04T23:59:59+00:00"
generated_at: "2026-06-05T04:38:43.480121+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Neurogene expands Rett syndrome gene therapy trial, adds high-dose cohort

## Summary
- Cohort 1 expanded from 5 to 8 patients; staggered dosing removed for parallel enrollment.
- New Cohort 2 with higher dose (3×10^15 vector genomes) added; first patient dosing expected Q2 2024.
- Third patient dosed in Cohort 1; no serious adverse events or overexpression-related toxicity observed.
- Interim Cohort 1 data expected Q4 2024; Cohort 2 data expected H2 2025.
- Targeted immunosuppression (rituximab, sirolimus) added for Cohort 2 to prevent AAV immune responses.

## SEC filing metadata
- accession: 0001193125-24-056852
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2024-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000119312524056852/0001193125-24-056852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000119312524056852/d754656d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-056852
- JSON: https://secwatch.observer/filing/0001193125-24-056852.json
- Plain text: https://secwatch.observer/filing/0001193125-24-056852.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.